Background: Many health systems are exploring how to implement low-dose computed tomography (LDCT) screening programs that are effective and patient-centered.
I
n 2011, the NLST (National Lung Screening Trial) found that annual screening with low-dose computed tomography (LDCT) substantially reduced mortality from lung cancer (1), the leading cause of cancer death in the United States (2) . Many health systems are still exploring how best to implement LDCT screening programs (3) . Several factors complicate implementation of such screening. First, the absolute risk reduction with screening varies greatly among eligible patients (4) . Second, LDCT screening can result in substantial harms and costs (1, 5) . Third, high competing (non-lung cancer) mortality and surgical risk (1) can offset the all-cause mortality benefit associated with reducing lung cancerspecific mortality. Finally, undergoing LDCT screening is widely considered to be a preference-sensitive decision for some eligible patients (that is, the most appropriate decision depends on how they value the tradeoffs and risk [6 -9] ). This complexity creates uncertainty about how best to promote high-benefit screening to patients while respecting individual preferences.
Beyond the potential population benefits of riskbased screening (4, 5, 10 -15) , important implementation questions remain. How can clinicians tailor recommendations to both clinical benefit and patient preferences? Given time demands on primary care providers, should the current requirements for detailed shared decision making from the Centers for Medicare & Medicaid Services be enforced for all patients, even those with a mortality benefit that is much higher (or lower) than average? To help guide clinicians in determining when screening is or is not highly preference-sensitive and prioritizing their limited time for personalizing recommendations for LDCT screening through detailed shared decision making (16), we developed a microsimulation model that was consistent with data from large randomized trials (1, 17, 18) , could generate individual estimates of the net benefit of screening, and allowed us to evaluate the sensitivity of the benefit to patient preferences. health states that individual patients would experience under 2 scenarios: 3 years of annual LDCT screening for lung cancer versus no screening (Supplement Figures 1 and 2 , available at Annals.org). The model used events occurring during the 6-year NLST study period to estimate lifetime quality-adjusted life-years (QALYs) as the primary outcome. Our primary goal was to examine the effect of preferences on the net benefit of screening, so we varied disutilities across a likely range to identify subgroups of patients facing preferencesensitive decisions about screening. Disutilities quantify the "degree of dislike" (for example, negative feelings about LDCT screening, screening outcomes, and follow-up care) by subtracting short-term reductions in quality of life (Appendix Table, available at Annals.org) from a person's life expectancy in each year that an event occurs (for example, LDCT screening or an invasive procedure). We derived base-case disutilities from a previously published decision analysis (20) . Thus, understanding how QALY gains vary across the range of disutilities (Appendix Table) is much more important than understanding isolated outcomes under the uncertain point estimates used in the base case. We also examined the effect of varying the rates of false-positive results and overdiagnosis associated with LDCT screening.
U.S.-Representative LDCT-Eligible Study Population
To estimate outcomes of lung cancer screening that are representative of the contemporary U.S. population, we used the National Health Interview Survey (NHIS) to simulate a nationally representative sample of 1 million persons aged 55 to 80 years who met the U.S. Preventive Services Task Force (USPSTF) criteria for heavy smoking (≥30 pack-years and ≤15 years since smoking cessation). The NHIS is an annual crosssectional survey that collects self-reported data on the noninstitutionalized U.S. population (21). We first used harmonized NHIS data from the Integrated Health Interview Series to create an initial data set of 14 416 respondents meeting current USPSTF criteria between 2010 and 2014. We then expanded the population on the basis of NHIS sampling weights using R, version 3.3.1 (22) , with multiple imputation for and reporting of missing data (section S.2 of the Supplement, available at Annals.org).
Microsimulation Model and Individualized Transition Probabilities

Nonscreened Cohort
Each smoker in the study population faced yearly transition probabilities of developing lung cancer (or not), dying of causes other than lung cancer (competing mortality), or dying of lung cancer. Patient-specific annual incidence of lung cancer was based on one of the best-performing validated risk models, which uses age, sex, smoking duration, average number of cigarettes per day, and years since quitting (23, 24) (all persons were assumed to have no asbestos exposure). We developed a prediction model from the control group of the PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) (18) to assign histology (25) of incident lung cancer cases, and we assigned lung cancer stage (Ia/b, II, IIIa/b, or IV [26] ) using SEER (Surveillance, Epidemiology, and End Results) data from 2005 to 2012, with conditioning on histology and sex. To determine lung cancer survival, we used a cure survival model in Cancer Survival Analysis Software (27) with log-normal distribution (28) fitted to SEER lung cancer data by sex, age group, histology, and stage and then further calibrated to match NLST lung cancer mortality. We derived competing mortality by using a previously published model, which uses age, sex, pack-years, and smoking status (29, 30) . The Appendix 
Screened Cohort
Persons in the screened cohort underwent 3 rounds of annual LDCT screening and had a positive or negative result. All persons with positive results had follow-up testing and possible invasive diagnostic procedures, complications, and diagnostic mortality at the rates reported in the NLST (1, 17) . A positive result could be false-positive (no lung cancer after further testing) or true-positive (lung cancer). Persons with lung cancer detected at an earlier preclinical stage could have experienced stage shift (detection and treatment prolonging time to lung cancer death), cure (prevention of lung cancer death due to lung resection) (31), or overdiagnosis (diagnosis of asymptomatic cancer that would never cause clinical disease or death in the absence of screening) (32). Other persons had a negative result, which could be true-negative (no lung cancer present) or false-negative (lung cancer was present but was missed because of the imperfect sensitivity of LDCT screening).
We based the sensitivity of the LDCT screening on previously published work (33) and calibrated it to the lung cancer incidence and mortality observed in the NLST. We based the specificity of each screening round on NLST results (1). To account for overdiagnosed lung cancer, we retrospectively increased the number of cases diagnosed in the screened cohort so that overdiagnosed cases represented 10% of all screen-detected cases. This was based on prior estimates from NLST and prior modeling studies (30, 34, 35 ) (section S.3 of the Supplement).
Model Assumptions
We assumed a 95% adherence rate for LDCT screening for the risk-stratified analysis. We assigned overdiagnosed cases preferentially to persons with higher risk for clinical lung cancer because most such cases probably grow very slowly, but we also conducted a sensitivity analysis assigning overdiagnosed cases randomly across all patients.
Quality-Adjusted Life Expectancy
We obtained utility (5, 36) and disutility (degree-ofdislike) (20) estimates from previously published models (Appendix Table) . We also assigned a disutility to each screening and follow-up imaging test (a quality-oflife deduction of 0.4 day or 9.6 hours per LDCT screen or follow-up imaging test in the base case) to account for the consequences of the screening or testing itself Shaded regions indicate 95% uncertainty ranges. LDCT = low-dose computed tomography; NNS = number needed to screen; QALY = qualityadjusted life-year. * Data are the 95% bootstrap uncertainty range for the mean NNS to avoid 1 all-cause death in each decile.
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(for example, time and travel costs; out-of-pocket cost; patient burden of undergoing LDCT screening and follow-up imaging; and potential negative psychological effects, such as distress from an indeterminate nodule) (section S.3 of the Supplement). Because of the inherent uncertainty in patient preferences, our primary aim was to evaluate how varying personalized disutility estimates over a broad range influenced the net benefit of LDCT screening (Appendix Table) .
Statistical Analysis
Outcomes and Uncertainty Analysis
Our primary outcome was QALY gains from LDCT versus no screening, with a focus on annual lung cancer risk and "pro-screening" patients with favorable screening preferences (minimal negative feelings) versus "anti-screening" patients with unfavorable preferences (stronger negative feelings). To provide clinical context, we performed these analyses for each percentile of baseline lung cancer risk and for 4 specific individualpatient scenarios ( Table 1) . We also examined QALY gains for each quintile of competing mortality risk. A 3% annual discount rate was applied to all QALY calculations. We estimated the uncertainty in our results by calculating 95% bootstrap uncertainty ranges and performing sensitivity analyses on key parameters.
Sensitivity Analysis
The NLST found a 20% relative risk reduction (RRR) for LDCT versus chest radiography, but our base-case model examined LDCT screening versus no screening. Primarily on the basis of the sensitivity of LDCT (33), we hypothesized that the RRR of LDCT versus no screening would be slightly more than 20%, reflecting a small benefit from annual chest radiography (for example, due to true-and false-positive results on chest radiography leading to CT), but we also examined a 20% RRR for LDCT screening versus no screening. Given substantial uncertainty about real-world rates of falsepositive LDCT results (suspicious results eventually found not to be cancer) (3, 37) and uncertainty about the true rate of overdiagnosis (lung cancer that never harms the patient) (18, 30, 34, 35), we tested falsepositive rates of 10% to 60% for each LDCT screen and overdiagnosis rates of 5% to 15% of all lung cancer cases found.
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RESULTS
Lung Cancer Diagnoses and Deaths
Supplement Table 11 (available at Annals.org) shows demographic characteristics of the U.S.-representative study population. Model estimates aligned well with lung cancer incidence, mortality, and stage distributions observed in the NLST and the PLCO (Supplement Figures 6  and 7 and Supplement Tables 9 and 10, available at Annals.org). Our simulations showed a 22.7% RRR in lung cancer mortality after 6.5 years of follow-up with 3 LDCT screens versus no screening (95% uncertainty range, 22.2% to 23.3%).
Heterogeneity of QALY Gains by Baseline Risk
Three rounds of annual LDCT screening led to 2700 (95% uncertainty range, 2600 to 2800) lifetime QALYs gained per 100 000 persons (10 qualityadjusted life-days per person). However, QALY gains varied substantially depending on risk for lung cancer (Figure 1 ), ranging from 830 per 100 000 persons in those with lower risk to 3500 per 100 000 persons in those with higher risk in our base case. The number needed to screen (NNS) to avoid 1 all-cause death varied across risk groups, from 537 to 572 in the lowestrisk decile of eligible persons to 95 to 98 in the highestrisk decile. Increasing QALY gains peaked once lung cancer risk neared the 70th percentile, mainly due to higher risk for competing noncancer causes of death (section S.7 of the Supplement, available at Annals .org). Although patient preferences also had a major effect on the net benefit of LDCT screening (Figure 1) , the average person with lung cancer risk between the 28th and 91st percentiles (that is, annual lung cancer risk between 0.3% and 1.3%) experienced net benefit, even under the assumption of anti-screening preferences.
Competing Mortality Risk
As expected, when competing mortality risk from noncancer causes increased, the benefit (incremental QALY gains) from LDCT screening decreased ( Figure 2 [top]), most strikingly for those in the highest quintile of competing risk (life expectancy <10.5 years), where LDCT screening was preference-sensitive across all percentiles of lung cancer risk ( Figure 2 [middle] ). On the other hand, for those in the 4 lower quintiles of competing mortality (life expectancy >10.5 years), the net benefit of LDCT screening continued to increase with lung cancer risk and was never preferencesensitive for annual lung cancer risk greater than 0.3% ( Figure 2 [bottom] ).
Preference-Sensitive and Preference-Insensitive Risk Thresholds for LDCT Screening
Combining the aforementioned results, we found that the clinical benefit of LDCT depended on the patient's life expectancy and annual risk for lung cancer.
For the approximately 52.9% of patients in our U.S.-representative population with sufficiently long life expectancy (median, ≥10.5 years) and high annual lung cancer risk (≥0.3%), preferences against screening in the range considered in the analysis would diminish the benefit of screening but would not alter its superiority (net positive QALY benefit). For a few eligible patients (<0.1%) with both limited life expectancy (<10.5 years) and low annual lung cancer risk (<0.3%), our base case showed possible net harm. For roughly 47%, the opti- Identifying Patients for Whom Lung Cancer Screening Is Preference-Sensitive ORIGINAL RESEARCH mal strategy depended on individual-patient preferences over the ranges considered in the models.
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Individual Scenarios
To provide additional clinical context, we simulated expected outcomes for 4 persons, each with a specific set of risk attributes, and present how differences in preferences would play a role in determining qualityadjusted life-day gains or losses for each ( Table 1) .
Sensitivity Analyses
Calibrating to a 20% RRR in mortality with LDCT screening versus no screening, we found that screening was preference-sensitive up to a 0.5% annual lung cancer risk, rather than the 0.3% risk threshold observed in our base case (Supplement Table 12 , available at Annals.org). Varying the false-positive rate from 10% to 60% was not highly influential in determining either the net benefit or preference sensitivity of screening. Varying the overdiagnosis rate from 5% to 15% did not have a large effect on net benefit for most persons, so screening remained preference-sensitive up to an annual lung cancer risk of approximately 0.3%, similar to our base case. However, the rate of overdiagnosis was potentially influential in determining net benefit and preference sensitivity among those at highest risk for lung cancer (due to the high competing mortality risk and shorter life expectancy) (section S.8 of the Supplement, available at Annals.org). Supplement Table 12 summarizes how all sensitivity analyses affected the preference-sensitive risk thresholds.
DISCUSSION
We found that the health gains of LDCT lung cancer screening vary considerably across the eligible population, with 3 factors being highly influential: risk for lung cancer, competing risks or life expectancy, and patient preferences. For eligible persons with annual lung cancer risk greater than 0.3% and life expectancy greater than 10 years, the benefits of LDCT screening overcame even highly negative views about screening and its downsides. For this high-benefit group, which represented roughly 50% of our U.S.-representative screening-eligible study population, the expected absolute mortality benefit was greater than for most other routinely recommended cancer screening interventions (38, 39). For eligible persons at lower lung cancer risk or with shorter life expectancy, LDCT screening was usually highly preference-sensitive. These results suggest an approach that may help clinicians improve and personalize LDCT screening discussions after first assessing the net benefit of screening for their individual patients. This personalized assessment of net benefit should focus on use of a validated prediction tool to calculate lung cancer risk (40, 41) and should also carefully consider life expectancy (42).
Of note, we also found that widely varying rates of false-positive findings (10% to 60%) made small differences in our results. Even when using large patient disutilities (stronger negative feelings) for false-positive findings, we found little effect on net benefit for higherrisk persons who were eligible for screening. This finding is particularly important given a recent report that false-positive LDCT results may be much higher in routine care than in clinical trials (3). Other modeling studies have found insensitivity to small screening-or treatment-related disutilities when the absolute risk reduction (that is, the absolute benefit) is high (43, 44) . On the other hand, we found that the rate of overdiagnosed lung cancer cases can influence the screening decision for a small group of eligible persons at very high risk, but only if overdiagnosis is strongly correlated with clinical lung cancer risk.
Previous research showed that LDCT screening was much more effective for persons in higher quintiles of lung cancer risk (4, 5, 10 -15) . A recent study also suggests that current smoking trends could enhance the advantages of risk-based LDCT screening over time (45) . Our objective was to move beyond the goal of optimizing risk-based eligibility criteria toward substantively informing a question at the core of delivering patient-centered care: "How should I present the pros and cons of screening for this eligible patient?" Our findings are thus highly relevant for those interested in taking a nuanced, patient-centered approach to discussing lung cancer screening. Our results suggest that for some high-risk, high-benefit patients (those with annual lung cancer risk >0.3% and long life expectancy), such as person C in Table 1 , lung cancer screening could generally be recommended during shared decision making. For such patients, the absolute mortality benefit of LDCT screening is on par with that of average-risk colon cancer screening (for example, an NNS of approximately 130 to avoid 1 cancer-specific death for 3 annual rounds of LDCT screening among persons in the seventh decile of lung cancer risk vs. an (23) is 1 externally validated model that accurately calculates annual risk and was used in the provider-facing tool developed using the results of this study (40). These rules can be converted to the following estimates for 5-, 6-, and 10-y lung cancer risk thresholds to facilitate use of risk prediction models that use other time frames: 1) 0.3% 1-y risk Х 2.0% 5-y risk Х 2.6% 6-y risk Х 5.2% 10-y risk, and 2) 1.3% 1-y risk Х 5.7% 5-y risk Х 6.9% 6-y risk Х 11.4% 10-y risk.
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NNS of approximately 50 for sigmoidoscopy every 5 years over a 25-year period) (38), and LDCT is considerably more effective than screening mammography (NNS of approximately 1000 to avoid 1 breast cancer death with 10 years of repeated screening mammography among women aged 50 to 59 years) (39) . An important caveat is that the large absolute mortality benefit of LDCT screening among high-risk patients translates into substantial QALY gains only when the patient also has a long life expectancy. Of course, patients always have the authority to make the final screening decision, so high-benefit patients with very strong negative feelings have the right to decide against LDCT screening, even if it is initially recommended. Such decisions should be respected, just as when patients decline colon cancer screening or other recommended interventions.
Our results demonstrate that LDCT screening is highly preference-sensitive for some eligible patients with a lower absolute mortality benefit (annual lung cancer risk <0.3% or life expectancy <10 years). Shared decision making is most important for this group but is complicated by the influence of several factors on the harm-benefit tradeoffs. This complexity makes it all but impossible for clinicians to estimate an individual patient's harm-benefit tradeoffs without a decision tool. Several online tools are available (40, 41, 46 -48), including patient-facing tools (41) and a provider-facing tool we developed using these study findings (40). To highlight how our results can help clinicians counseling eligible patients about lung cancer screening, we summarize our findings in the form of simple, practical rules of thumb in Table 2 .
Our study has limitations. First, available risk prediction models use different individual characteristics to estimate lung cancer risk (such as race, family history, and body mass index), which can lead to substantially different absolute risk estimates for the same person (24) . Also, for a given population, agreement between predicted and observed lung cancer risk (calibration) will vary across risk models. This variation can lead to misclassification across a decision threshold, such as determining when a person is in a high-benefit category versus a preference-sensitive category. Still, other methods of categorizing individual patients will likely lead to greater misclassification. Our approach of using a reasonably accurate risk prediction model to determine the degree of benefit likely minimizes misclassification errors compared with other methods (for example, using current USPSTF eligibility criteria for LDCT screening can lead to misclassification of high-risk persons who are aged 54 years) (10 -14). Also, any method that uses detailed smoking history will lead to misclassification due to unavoidable measurement error (such as that caused by underreporting or overreporting of smoking history information or patient misunderstanding about the meaning of "average packs per day").
Second, the risk thresholds we identified in this study, which are based on the "true" lung cancer risk, are likely to vary depending on the structure of the microsimulation model used. Thus, the rules of thumb presented in Table 2 should be taken as rough guideposts rather than strict cutoffs.
Third, we modeled a 95% rate of adherence for all persons, which is higher than is likely to occur. Although considering adherence is appropriate for a policy analysis of population effects, examining net benefit under the assumption of high adherence is a reasonable way to examine our question of how to personalize screening discussions.
Fourth, our findings are specific to 3 annual screening rounds given that we used parameter estimates from the NLST, which studied only 3 screenings. The cumulative benefit of screening would differ with longer periods of annual screening but would require additional assumptions. In addition, limiting our analyses to outcomes from 3 annual screenings is clinically useful because it is reasonable for clinicians to discuss the value of ongoing screening at least every 3 to 5 years with eligible patients. This not only allows for discussion of important new evidence on screening but also allows clinicians and patients to discuss any changes to the patient's circumstances, underlying health, or preferences. Also, although we focused on the population meeting the USPSTF criteria, our results should extend beyond them because both lung cancer and competing risk were taken into account.
Fifth, we assumed the same rates of false-positive findings, invasive procedures, and complications across the study population. This is supported by prior studies demonstrating that rates of harm do not vary nearly as dramatically as the absolute mortality reduction (11) . Moreover, substantial variation in the rates of falsepositive findings did not substantially affect our results.
Finally, we assumed that all overdiagnosed lung cancer cases were stage IA adenocarcinomas. This assumption could have resulted in underestimation of the negative effect of a specific rate of overdiagnosis. However, we examined net benefit with screening over a broad range of overdiagnosis rates and also assessed the effect of 2 methods of assigning overdiagnosis, thus incorporating uncertainty about overdiagnosis in the real world.
In conclusion, our results support the importance of personalizing the harm-benefit assessment of LDCT lung cancer screening for informing screening decisions rather than uniformly recommending or withholding a recommendation for eligible patients. Because the harm-benefit considerations can be complex, we have created and made available a Web-based decision tool that incorporates the rules of thumb derived from our findings to facilitate personalized discussions about LDCT screening (40). 
